Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Packer

Showing results (631-640 of 706) with videos related to

Pageof 71
Sort By:
Developmental Cell|August 24, 2021
Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitorsEmmanuelle S Jecrois, Wang Zheng, Miriam Bornhorst, et al.
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium StudyMark W Kieran, Roger J Packer, Arzu Onar, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Neuro-Oncology Advances|October 22, 2025
Challenges in diagnostics and treatment of infant-type hemispheric gliomasLudmila Papusha, Margarita Zaytseva, Maria Senchenko, et al.
Annals of Neurology|April 18, 2014
Gender as a disease modifier in neurofibromatosis type 1 optic pathway gliomaMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2018
Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid BiopsyEshini Panditharatna, Lindsay B Kilburn, Mariam S Aboian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiationP R Thomas, M Deutsch, J L Kepner, et al.
Cell Reports. Medicine|August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertionsAisha M Swaih, Sara Talbot, Adriana Savoca, et al.
Neuro-Oncology|October 29, 2025
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survivalAuthors Kyle S Smith, Sandeep K Dhanda, Catherine A Billups, et al.
Pageof 71

Showing results (631-640 of 706) with videos related to

Sort By:
Pageof 71
Developmental Cell|August 24, 2021
Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitorsEmmanuelle S Jecrois, Wang Zheng, Miriam Bornhorst, et al.
Neuro-Oncology|April 28, 2017
Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committeeKatherine E Warren, Gilbert Vezina, Tina Y Poussaint, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium StudyMark W Kieran, Roger J Packer, Arzu Onar, et al.
Neuro-Oncology|March 25, 2017
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) studyAnuradha Banerjee, Regina I Jakacki, Arzu Onar-Thomas, et al.
Neuro-Oncology Advances|October 22, 2025
Challenges in diagnostics and treatment of infant-type hemispheric gliomasLudmila Papusha, Margarita Zaytseva, Maria Senchenko, et al.
Annals of Neurology|April 18, 2014
Gender as a disease modifier in neurofibromatosis type 1 optic pathway gliomaMichael J Fisher, Michael Loguidice, David H Gutmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2018
Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid BiopsyEshini Panditharatna, Lindsay B Kilburn, Mariam S Aboian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiationP R Thomas, M Deutsch, J L Kepner, et al.
Cell Reports. Medicine|August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertionsAisha M Swaih, Sara Talbot, Adriana Savoca, et al.
Neuro-Oncology|October 29, 2025
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survivalAuthors Kyle S Smith, Sandeep K Dhanda, Catherine A Billups, et al.
Pageof 71